Celcuity’s (CELC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note published on Monday,Benzinga reports. They currently have a $27.00 price target on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $29.00 price target on shares of Celcuity in a research note on Thursday, May 15th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $30.80.

Celcuity Price Performance

Shares of CELC opened at $10.69 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. Celcuity has a fifty-two week low of $7.58 and a fifty-two week high of $19.77. The firm has a 50-day simple moving average of $10.15 and a 200-day simple moving average of $11.61. The company has a market capitalization of $404.50 million, a price-to-earnings ratio of -4.10 and a beta of 0.56.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. On average, equities research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.

Institutional Investors Weigh In On Celcuity

A number of hedge funds have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP increased its position in Celcuity by 42.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,678,553 shares of the company’s stock worth $35,062,000 after purchasing an additional 803,575 shares during the period. Bleakley Financial Group LLC acquired a new position in Celcuity during the 4th quarter worth approximately $146,000. Vanguard Group Inc. increased its position in Celcuity by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 1,651,981 shares of the company’s stock worth $21,624,000 after purchasing an additional 24,429 shares during the period. Corebridge Financial Inc. increased its position in Celcuity by 12.9% during the 4th quarter. Corebridge Financial Inc. now owns 16,256 shares of the company’s stock worth $213,000 after purchasing an additional 1,858 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Celcuity by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company’s stock worth $3,112,000 after purchasing an additional 16,035 shares during the period. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.